Beyond GIST, regorafenib’s clinical utility was further expanded in hepatocellular carcinoma (HCC), where the phase III RESORCE trial confirmed its benefit as second-line therapy after sorafenib, representing the first agent to demonstrate a survival advantage in patients progressing on prior VEGFR-targeted treatment [120]. The gene discussed is KDR; the disease is gastrointestinal stromal tumor.